3.30
5.17%
-0.18
Chromadex Corp stock is currently priced at $3.30, with a 24-hour trading volume of 256.29K.
It has seen a -5.17% decreased in the last 24 hours and a -16.88% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.54 pivot point. If it approaches the $3.16 support level, significant changes may occur.
Previous Close:
$3.48
Open:
$3.5
24h Volume:
256.29K
Market Cap:
$249.28M
Revenue:
$83.57M
Net Income/Loss:
$-4.94M
P/E Ratio:
-36.67
EPS:
-0.09
Net Cash Flow:
$6.97M
1W Performance:
-3.51%
1M Performance:
-16.88%
6M Performance:
+130.77%
1Y Performance:
+112.90%
Chromadex Corp Stock (CDXC) Company Profile
Name
Chromadex Corp
Sector
Industry
Phone
949-419-0288
Address
10005 Muirlands Boulevard, Suite G, Irvine
Chromadex Corp Stock (CDXC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
Mar-08-22 | Initiated | ROTH Capital | Buy |
Oct-16-19 | Initiated | Oppenheimer | Outperform |
Feb-14-19 | Initiated | B. Riley FBR | Buy |
Nov-27-17 | Resumed | H.C. Wainwright | Buy |
Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Chromadex Corp Stock (CDXC) Latest News
Chromadex Corp (CDXC) receives a Perform rating from Oppenheimer – Knox Daily - Knox Daily
Knox Daily
HC Wainwright Equities Analysts Reduce Earnings Estimates for ChromaDex Co. (NASDAQ:CDXC) - MarketBeat
MarketBeat
ChromaDex (NASDAQ:CDXC) Stock Rating Reaffirmed by HC Wainwright - Defense World
Defense World
Roth Capital Research Analysts Lower Earnings Estimates for ChromaDex Co. (NASDAQ:CDXC) - Defense World
Defense World
Q1 2025 EPS Estimates for ChromaDex Co. Cut by Roth Capital (NASDAQ:CDXC) - MarketBeat
MarketBeat
ChromaDex Corp (CDXC) Q1 2024 Earnings: Aligns with EPS Projections, Misses Revenue Estimates - Yahoo Finance
Yahoo Finance
Chromadex Corp Stock (CDXC) Financials Data
Chromadex Corp (CDXC) Revenue 2024
CDXC reported a revenue (TTM) of $83.57 million for the quarter ending December 31, 2023, a +15.99% rise year-over-year.
Chromadex Corp (CDXC) Net Income 2024
CDXC net income (TTM) was -$4.94 million for the quarter ending December 31, 2023, a +70.15% increase year-over-year.
Chromadex Corp (CDXC) Cash Flow 2024
CDXC recorded a free cash flow (TTM) of $6.97 million for the quarter ending December 31, 2023, a +145.16% increase year-over-year.
Chromadex Corp (CDXC) Earnings per Share 2024
CDXC earnings per share (TTM) was -$0.07 for the quarter ending December 31, 2023, a +69.57% growth year-over-year.
Chromadex Corp Stock (CDXC) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Jaksch Frank L Jr | Director |
Jun 12 '23 |
Buy |
1.69 |
7,000 |
11,830 |
231,339 |
Fried Robert N | Chief Executive Officer |
May 31 '23 |
Buy |
1.42 |
7,000 |
9,940 |
95,001 |
Rubin Steven D | Director |
May 25 '23 |
Buy |
1.46 |
7,000 |
10,220 |
7,000 |
About Chromadex Corp
ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation has a strategic partnership for healthy aging research with the Jiangxi Provincial Government, the People's Republic of China. ChromaDex Corporation is based in Irvine, California.
Cap:
|
Volume (24h):